abstract: UNASSIGNED: The most important lesion to be overlooked when performing @entity227 inspection of the lungs is @entity55 . The aim of the present study was to assess the additional @entity1 health risk represented by overlooking cases of @entity295 represented by @entity55 in finisher @entity1707 , when conducting @entity227 compared to palpation of the lungs, as is the traditional meat inspection procedure. An examination of bacteria isolated from 19 finisher @entity1707 identified with @entity55 at traditional meat inspection was undertaken. From each @entity1707 samples were taken from various organs (lungs, spleen, heart, liver and kidney), from the @entity2720 (A. carpi) and flexor muscle (M. flexor digitorum superficialis) on the right foreleg. These data were included in a risk assessment following OIE guidelines. Bacteria were isolated from 78 out of 127 tissue and swap samples taken (61% positive samples). @entity794 (N=37) was the most frequently isolated bacterium. The predominant site of @entity794 was the lung. @entity794 was detected although less frequently in low numbers in some organs (<100CFU/sample) and muscle samples (<10CFU/sample). Only one @entity794 isolate was found. @entity15029 (N=24) was the second most commonly found bacterium. There was no predominant site and the number of @entity15029 was less than 50CFU per sample. The risk of a food-borne intoxication from @entity794 in relation to @entity295 in @entity1707 was considered very low due to the low quantitative numbers of @entity794 in muscle tissue samples. Implementing @entity227 inspection will reduce the exposure of @entity794 due to less cross-contamination and handling of the plucks by the meat inspectors. The @entity1 health risk associated with @entity15029 was considered very low, due to the limited zoonotic potential of this bacterium. In conclusion, the additional @entity1 health risk in relation to possibly overlooking @entity295 in Danish finisher @entity1707 was considered negligible when conducting @entity227 compared to traditional meat inspection.

title: Assessment of @entity1 health risk associated with @entity295 in Danish finisher @entity1707 when conducting XXXX inspection of the lungs.

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual-only']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['embolic pneumonia']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus', 'MRSA', 'S. aureus']

entities_list: @entity2720 :: ('MESH:D007592', 'Disease') :: ['carpal joints']

entities_list: @entity15029 :: ('1292', 'Species') :: ['Staphylococcus warneri', 'S. warneri']

answer: @entity227 :: (MESH:D014786,Disease) :: ['visual-only']


abstract: UNASSIGNED: The most important lesion to be overlooked when performing @entity227 inspection of the lungs is @entity55 . The aim of the present study was to assess the additional @entity1 health risk represented by overlooking cases of @entity295 represented by @entity55 in finisher @entity1707 , when conducting @entity227 compared to palpation of the lungs, as is the traditional meat inspection procedure. An examination of bacteria isolated from 19 finisher @entity1707 identified with @entity55 at traditional meat inspection was undertaken. From each @entity1707 samples were taken from various organs (lungs, spleen, heart, liver and kidney), from the @entity2720 (A. carpi) and flexor muscle (M. flexor digitorum superficialis) on the right foreleg. These data were included in a risk assessment following OIE guidelines. Bacteria were isolated from 78 out of 127 tissue and swap samples taken (61% positive samples). @entity794 (N=37) was the most frequently isolated bacterium. The predominant site of @entity794 was the lung. @entity794 was detected although less frequently in low numbers in some organs (<100CFU/sample) and muscle samples (<10CFU/sample). Only one @entity794 isolate was found. @entity15029 (N=24) was the second most commonly found bacterium. There was no predominant site and the number of @entity15029 was less than 50CFU per sample. The risk of a food-borne intoxication from @entity794 in relation to @entity295 in @entity1707 was considered very low due to the low quantitative numbers of @entity794 in muscle tissue samples. Implementing @entity227 inspection will reduce the exposure of @entity794 due to less cross-contamination and handling of the plucks by the meat inspectors. The @entity1 health risk associated with @entity15029 was considered very low, due to the limited zoonotic potential of this bacterium. In conclusion, the additional @entity1 health risk in relation to possibly overlooking @entity295 in Danish finisher @entity1707 was considered negligible when conducting @entity227 compared to traditional meat inspection.

title: Assessment of @entity1 health risk associated with XXXX in Danish finisher @entity1707 when conducting @entity227 inspection of the lungs.

answer: @entity295 :: (MESH:D018805,Disease) :: ['pyaemia']


abstract: UNASSIGNED: The most important lesion to be overlooked when performing @entity227 inspection of the lungs is @entity55 . The aim of the present study was to assess the additional @entity1 health risk represented by overlooking cases of @entity295 represented by @entity55 in finisher @entity1707 , when conducting @entity227 compared to palpation of the lungs, as is the traditional meat inspection procedure. An examination of bacteria isolated from 19 finisher @entity1707 identified with @entity55 at traditional meat inspection was undertaken. From each @entity1707 samples were taken from various organs (lungs, spleen, heart, liver and kidney), from the @entity2720 (A. carpi) and flexor muscle (M. flexor digitorum superficialis) on the right foreleg. These data were included in a risk assessment following OIE guidelines. Bacteria were isolated from 78 out of 127 tissue and swap samples taken (61% positive samples). @entity794 (N=37) was the most frequently isolated bacterium. The predominant site of @entity794 was the lung. @entity794 was detected although less frequently in low numbers in some organs (<100CFU/sample) and muscle samples (<10CFU/sample). Only one @entity794 isolate was found. @entity15029 (N=24) was the second most commonly found bacterium. There was no predominant site and the number of @entity15029 was less than 50CFU per sample. The risk of a food-borne intoxication from @entity794 in relation to @entity295 in @entity1707 was considered very low due to the low quantitative numbers of @entity794 in muscle tissue samples. Implementing @entity227 inspection will reduce the exposure of @entity794 due to less cross-contamination and handling of the plucks by the meat inspectors. The @entity1 health risk associated with @entity15029 was considered very low, due to the limited zoonotic potential of this bacterium. In conclusion, the additional @entity1 health risk in relation to possibly overlooking @entity295 in Danish finisher @entity1707 was considered negligible when conducting @entity227 compared to traditional meat inspection.

title: Assessment of @entity1 health risk associated with @entity295 in Danish finisher XXXX when conducting @entity227 inspection of the lungs.

answer: @entity1707 :: (9823,Species) :: ['pigs']


abstract: UNASSIGNED: The most important lesion to be overlooked when performing @entity227 inspection of the lungs is @entity55 . The aim of the present study was to assess the additional @entity1 health risk represented by overlooking cases of @entity295 represented by @entity55 in finisher @entity1707 , when conducting @entity227 compared to palpation of the lungs, as is the traditional meat inspection procedure. An examination of bacteria isolated from 19 finisher @entity1707 identified with @entity55 at traditional meat inspection was undertaken. From each @entity1707 samples were taken from various organs (lungs, spleen, heart, liver and kidney), from the @entity2720 (A. carpi) and flexor muscle (M. flexor digitorum superficialis) on the right foreleg. These data were included in a risk assessment following OIE guidelines. Bacteria were isolated from 78 out of 127 tissue and swap samples taken (61% positive samples). @entity794 (N=37) was the most frequently isolated bacterium. The predominant site of @entity794 was the lung. @entity794 was detected although less frequently in low numbers in some organs (<100CFU/sample) and muscle samples (<10CFU/sample). Only one @entity794 isolate was found. @entity15029 (N=24) was the second most commonly found bacterium. There was no predominant site and the number of @entity15029 was less than 50CFU per sample. The risk of a food-borne intoxication from @entity794 in relation to @entity295 in @entity1707 was considered very low due to the low quantitative numbers of @entity794 in muscle tissue samples. Implementing @entity227 inspection will reduce the exposure of @entity794 due to less cross-contamination and handling of the plucks by the meat inspectors. The @entity1 health risk associated with @entity15029 was considered very low, due to the limited zoonotic potential of this bacterium. In conclusion, the additional @entity1 health risk in relation to possibly overlooking @entity295 in Danish finisher @entity1707 was considered negligible when conducting @entity227 compared to traditional meat inspection.

title: Assessment of XXXX health risk associated with @entity295 in Danish finisher @entity1707 when conducting @entity227 inspection of the lungs.

answer: @entity1 :: (9606,Species) :: ['human']


abstract: @entity27773 , lectin-like oxidized low-density lipoprotein (LDL) receptor-1, is a single transmembrane receptor mainly expressed on endothelial cells. @entity27773 mediates the uptake of oxidized LDL, an early step in @entity731 ; however, little is known about whether @entity27773 is involved in angiogenesis during tissue @entity63 . Therefore, we examined the role of @entity27773 in @entity63 -induced angiogenesis in the hindlimbs of @entity27773 knockout (KO) @entity19 . Angiogenesis was evaluated in a surgically induced hindlimb @entity63 model using laser Doppler blood flowmetry (LDBF) and histological @entity2478 ( @entity2478 ) and @entity2101 ( @entity2101 ). After right hindlimb @entity63 , the @entity63 /nonischemic hindlimb blood flow ratio was persistently lower in @entity5559 -1 KO @entity19 than in @entity164 ( @entity164 ) @entity19 . @entity2478 and @entity2101 were significantly smaller in @entity5559 -1 KO @entity19 than in @entity164 @entity19 on postoperative day 14. Immunohistochemical analysis revealed that the number of macrophages infiltrating @entity63 tissues was significantly smaller in @entity5559 -1 KO @entity19 than in @entity164 @entity19 . The number of infiltrated macrophages expressing @entity1611 was also significantly smaller in @entity5559 -1 KO @entity19 than in @entity164 @entity19 . Western blot analysis and ROS production assay revealed that @entity5559 - KO @entity19 show significant decrease in @entity8930 expression, ROS production and @entity1965 expression, the phosphorylation of @entity1995 and NF-kB p65 subunit as well as expression of redox-sensitive @entity6580 ( @entity6580 ) and @entity27773 itself in @entity63 muscles, which is supposed to be required for macrophage infiltration expressing angiogenic factor @entity1611 . Reduction of @entity1611 expression successively suppressed the phosphorylation of Akt and eNOS, which accelerated angiogenesis, in the @entity63 leg of @entity5559 -1 KO @entity19 . Our findings indicate that @entity27773 plays an important role in @entity63 -induced angiogenesis by 1) @entity8930 -ROS-NF-kB activation, 2) upregulated expression of adhesion molecules: @entity6580 and @entity27773 ) promoting macrophage infiltration, which expresses angiogenic factor @entity1611 .

title: XXXX Plays an Important Role in @entity63 -Induced Angiogenesis of Limbs.

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia', 'ischemic']

entities_list: @entity2478 :: ('MESH:D019559', 'Disease') :: ['CD', 'capillary density']

entities_list: @entity2101 :: ('MESH:C538394', 'Disease') :: ['AD', 'arteriole density']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity6580 :: ('22329(Tax:10090)', 'Gene') :: ['VCAM-1', 'vascular cell adhesion molecule-1']

answer: @entity27773 :: (108078(Tax:10090),Gene) :: ['LOX-1']


abstract: @entity27773 , lectin-like oxidized low-density lipoprotein (LDL) receptor-1, is a single transmembrane receptor mainly expressed on endothelial cells. @entity27773 mediates the uptake of oxidized LDL, an early step in @entity731 ; however, little is known about whether @entity27773 is involved in angiogenesis during tissue @entity63 . Therefore, we examined the role of @entity27773 in @entity63 -induced angiogenesis in the hindlimbs of @entity27773 knockout (KO) @entity19 . Angiogenesis was evaluated in a surgically induced hindlimb @entity63 model using laser Doppler blood flowmetry (LDBF) and histological @entity2478 ( @entity2478 ) and @entity2101 ( @entity2101 ). After right hindlimb @entity63 , the @entity63 /nonischemic hindlimb blood flow ratio was persistently lower in @entity5559 -1 KO @entity19 than in @entity164 ( @entity164 ) @entity19 . @entity2478 and @entity2101 were significantly smaller in @entity5559 -1 KO @entity19 than in @entity164 @entity19 on postoperative day 14. Immunohistochemical analysis revealed that the number of macrophages infiltrating @entity63 tissues was significantly smaller in @entity5559 -1 KO @entity19 than in @entity164 @entity19 . The number of infiltrated macrophages expressing @entity1611 was also significantly smaller in @entity5559 -1 KO @entity19 than in @entity164 @entity19 . Western blot analysis and ROS production assay revealed that @entity5559 - KO @entity19 show significant decrease in @entity8930 expression, ROS production and @entity1965 expression, the phosphorylation of @entity1995 and NF-kB p65 subunit as well as expression of redox-sensitive @entity6580 ( @entity6580 ) and @entity27773 itself in @entity63 muscles, which is supposed to be required for macrophage infiltration expressing angiogenic factor @entity1611 . Reduction of @entity1611 expression successively suppressed the phosphorylation of Akt and eNOS, which accelerated angiogenesis, in the @entity63 leg of @entity5559 -1 KO @entity19 . Our findings indicate that @entity27773 plays an important role in @entity63 -induced angiogenesis by 1) @entity8930 -ROS-NF-kB activation, 2) upregulated expression of adhesion molecules: @entity6580 and @entity27773 ) promoting macrophage infiltration, which expresses angiogenic factor @entity1611 .

title: @entity27773 Plays an Important Role in XXXX -Induced Angiogenesis of Limbs.

answer: @entity63 :: (MESH:D007511,Disease) :: ['Ischemia']


abstract: BACKGROUND: Because the prognosis of advanced @entity2622 is poor, and has improved very little in the last 20 years, a prospective study was initiated to evaluate the feasibility, response and @entity137 of concomitant chemoradiotherapy for such cervical @entity5 . METHODS: From May 1992 to December 1992, 22 @entity1 entered the study, 21 of them completed the entire treatment. Their ages ranged from 47 to 72 years, median 57. There were 16 FIGO stage IIIB, and 5 stage IIB. Radiotherapy was administered using 1.8 Gy/day, five days a week, to the whole pelvis (50.4 Gy/28 fractions) with or without parametrial boost according to the @entity5 response. Intracavitary brachytherapy 5 Gy x five to six times was given after one or two weeks of rest. Chemotherapy consisted of @entity2879 100 mg/m2 day 1 + @entity900 50 mg/m2 day 1 + @entity1732 25 mg/m2/day day 2-3, repeated every two weeks during external irradiation. RESULTS: All 21 eligible @entity1 achieved complete response, sustaining during a median follow-up time of 12 months. All the initially elevated @entity5 markers (SCC, @entity787 , CA-125) returned to normal range after treatment. The @entity137 was well tolerated. CONCLUSIONS: Concomitant chemoradiotherapy for advanced @entity2622 is both feasible and effective, with acceptable @entity137 . Long-term follow-up is mandatory, and a randomized trial to confirm the superiority of this protocol will be started soon.

title: Concomitant chemoradiotherapy for advanced epidermoid XXXX : a preliminary report.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity2622 :: ('MESH:D002583', 'Disease') :: ['carcinoma of the uterine cervix', 'cervical carcinoma']

entities_list: @entity2879 :: ('MESH:D005047', 'Chemical') :: ['etoposide']

entities_list: @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']

answer: @entity2622 :: (MESH:D002583,Disease) :: ['carcinoma of the uterine cervix']


abstract: BACKGROUND: This retrospective study evaluated the length of cerebellar retraction and the changes of intraoperative brainstem auditory evoked potential (BAEP) during microvascular decompression (MVD), and assessed the predictive value of the @entity393 as a prognostic indicator for the treatment outcome of @entity1649 ( @entity1649 ). METHODS: This series included 1,518 consecutive @entity1 affected with @entity1649 who underwent MVD, during which BAEP was monitored. @entity1 were divided into two groups based on whether @entity393 occurred following decompression or not. Each @entity1 underwent a similar procedure performed by one neurosurgeon. The two @entity1 groups were matched with regard to sex, age, and degree of @entity2473 . RESULTS: Among the 1,518 @entity1 , 106 (6.98  %) displayed functional hearing changes. @entity393 was permanent in 12 @entity1 (0.79  %). Of the 1,412 @entity1 with stationary hearing compared with preoperative audiometry, 96 @entity1 were selected who were individually matched with respect to sex, age, and degree of @entity2473 . BAEP changed immediately after cerebellar retraction in 7 of 12 @entity393 @entity1 , suggesting the importance of retraction on hearing outcomes. The distance from the cerebellar surface of the petrous temporal bone to the neurovascular compression point was measured. The median distance of cerebellar retraction in the @entity393 group was 13.77  mm, which was longer than the median distance in the control group. CONCLUSIONS: Preoperative measurement of the cerebellar retraction distance can be a valuable clue to predict and prevent postoperative @entity393 in MVD for @entity1649 .

title: Cerebellar retraction and XXXX after microvascular decompression for @entity1649 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss', 'hearing-loss', 'Hearing loss']

entities_list: @entity1649 :: ('MESH:D019569', 'Disease') :: ['hemifacial spasm', 'HFS']

answer: @entity393 :: (MESH:D034381,Disease) :: ['hearing loss']


abstract: BACKGROUND: This retrospective study evaluated the length of cerebellar retraction and the changes of intraoperative brainstem auditory evoked potential (BAEP) during microvascular decompression (MVD), and assessed the predictive value of the @entity393 as a prognostic indicator for the treatment outcome of @entity1649 ( @entity1649 ). METHODS: This series included 1,518 consecutive @entity1 affected with @entity1649 who underwent MVD, during which BAEP was monitored. @entity1 were divided into two groups based on whether @entity393 occurred following decompression or not. Each @entity1 underwent a similar procedure performed by one neurosurgeon. The two @entity1 groups were matched with regard to sex, age, and degree of @entity2473 . RESULTS: Among the 1,518 @entity1 , 106 (6.98  %) displayed functional hearing changes. @entity393 was permanent in 12 @entity1 (0.79  %). Of the 1,412 @entity1 with stationary hearing compared with preoperative audiometry, 96 @entity1 were selected who were individually matched with respect to sex, age, and degree of @entity2473 . BAEP changed immediately after cerebellar retraction in 7 of 12 @entity393 @entity1 , suggesting the importance of retraction on hearing outcomes. The distance from the cerebellar surface of the petrous temporal bone to the neurovascular compression point was measured. The median distance of cerebellar retraction in the @entity393 group was 13.77  mm, which was longer than the median distance in the control group. CONCLUSIONS: Preoperative measurement of the cerebellar retraction distance can be a valuable clue to predict and prevent postoperative @entity393 in MVD for @entity1649 .

title: Cerebellar retraction and @entity393 after microvascular decompression for XXXX .

answer: @entity1649 :: (MESH:D019569,Disease) :: ['hemifacial spasm']


abstract: BACKGROUND: Care management has become a widespread strategy for improving @entity102 care. However, primary care provider (PCP) participation in programs has been poor. Because the success of care management relies on provider engagement, understanding provider perspectives is necessary. OBJECTIVE: Our goal was to identify care management functions most valuable to PCPs in @entity101 treatment. DESIGN: Six focus groups were conducted to discuss current challenges in @entity101 care and identify specific functions of care management that would improve care. @entity1 : The study included 39 PCPs (participation rate: 83 %) representing six clinics, two of which care for large African American populations and four that are in underserved locations, in the greater Baltimore metropolitan area. APPROACH: This was a qualitative analysis of focus groups, using grounded theory and iterative coding. KEY RESULTS: Providers desired achieving blood pressure control more rapidly. Collaborating with care managers who obtain ongoing @entity1 data would allow treatment plans to be tailored to the changing life conditions of @entity1 . The P.A.R.T.N.E.R. framework summarizes the care management functions that providers reported were necessary for effective collaboration: Partner with @entity1 , providers, and the community; Arrange follow-up care; Resolve barriers to adherence; Track treatment response and progress; Navigate the health care system with @entity1 ; Educate @entity1 _ Engage @entity1 in self-management; Relay information between @entity1 and/or provider(s). CONCLUSIONS: The P.A.R.T.N.E.R. framework is the first to offer a checklist of care management functions that may promote successful collaboration with PCPs. Future research should examine the validity of this framework in various settings and for diverse @entity1 populations affected by @entity102 .

title: Provider perspectives on essential functions for care management in the collaborative treatment of XXXX : the P.A.R.T.N.E.R. framework.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PARTICIPANTS']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic illness', 'chronic diseases']

answer: @entity101 :: (MESH:D006973,Disease) :: ['hypertension']


abstract: OBJECTIVES: This retrospective study evaluated the feasibility and related outcome of @entity358 banding (I-PAB). METHODS: Thirty-two @entity1 underwent I-PAB between July 2006 and April 2014. The median age and weight were 60 days (range: 5 days to 4.2 years) and 3.7 kg (range: 2.6-13.0 kg), respectively. Cardiac diagnoses included single ventricle morphology (n = 11), complex @entity1757 (n = 11), balanced @entity474 (n = 3), @entity4263 (n = 2) and @entity8521 with @entity1757 (n = 5). On cardiopulmonary bypass (CPB), 2 I-PAB modifications with either 1 (n = 24) or 2 ('hour-glass-technique', n = 8) fenestrated pericardial patches were performed. RESULTS: The median fenestration size was 5 mm (range: 4-6.5 mm). In 18 @entity1 I-PAB was a solitary procedure; in 3 of them the decision was made intraoperatively. There was no hospital mortality. The median interval to debanding was 189 days (range: 112 days to 2.6 years). During this period, we observed a significant increase in the pressure gradient over I-PAB (P < 0.01), whereas arterial saturations remained stable. Four @entity1 received balloon dilatation of I-PAB to prolong the palliation period. No @entity1 experienced band occlusion, @entity120 related to I-PAB, @entity301 . Debanding was performed in 27 @entity1 and one of them required pulmonary patch arterioplasty due to I-PAB-associated @entity358 . Three @entity1 are still awaiting further surgery. There were 2 late deaths prior to, and 3 after debanding, all not related to I-PAB. CONCLUSIONS: I-PAB with an exactly defined internal orifice is feasible and effective. Although arterial saturations seem to remain stable, balloon dilatation of I-PAB can be performed safely and efficiently in order to prolong the palliation period. The rate of I-PAB-related complications is low, which might improve the long-term @entity1 outcome. Therefore, despite requiring CPB, I-PAB is our institutional preference for @entity1 who require pulmonary artery banding.

title: Feasibility and related outcome of XXXX banding.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient']

entities_list: @entity8521 :: ('MESH:D001015', 'Disease') :: ['aortic arch hypoplasia']

entities_list: @entity301 :: ('MESH:D003327', 'Disease') :: ['coronary or pulmonary valve impairment']

entities_list: @entity1757 :: ('MESH:D006345', 'Disease') :: ['ventricular septal defects']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension']

entities_list: @entity474 :: ('MESH:C562831', 'Disease') :: ['atrioventricular septal defects']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['intraluminal pulmonary artery', 'pulmonary trunk distortion']

entities_list: @entity4263 :: ('MESH:C535426', 'Disease') :: ['congenitally corrected transposition of the great arteries']

answer: @entity358 :: (MESH:D008171,Disease) :: ['intraluminal pulmonary artery']


abstract: PURPOSE: @entity32 ( @entity32 ) are known to increase the risk of cardiovascular (CV) and renal incidences,  especially  at higher doses and upon long term use. However, the available reports are criticized for lack of specificity, grouping of vastly different outcomes together and ignoring the heterogeneity among @entity32 . In this systematic review, we are reporting CV/renal risks associated with @entity9213 , stratified into myocardial, vascular, renal risk categories, to address the differential nature of @entity32 effects on different body systems. We are also reporting composite CV/renal risk to present overall risk associated with various covariates. METHODS: We searched  the online healthcare databases for observational studies or randomized controlled trials, reporting myocardial or all-cause mortality outcome (>90  days exposure) and/or vascular/renal outcomes (any exposure) after @entity9213 use, published until April 2014. The combined odd ratio values (OR'; 95  % CI) were calculated using the random effect inverse variance model. RESULTS: We found 19 eligible studies  out of 2,422  reports. @entity9213 demonstrated a low increase in composite risk (OR' 1.14; CI 1.04-1.25) which was mainly vascular in nature (OR' 1.35; CI 1.18-1.55] as it did not elevate myocardial (OR' 1.13; CI 0.98-1.32) or renal (OR', 0.99; CI 0.72-1.35) risks. Relative to @entity9213 , other @entity32 increased the composite risk, in a dose-dependent fashion, in the following order: @entity13586  >  @entity3352  >  @entity3522  >  @entity12698  >  @entity1623  >  @entity5018 . OR' was also influenced by type of disease and the comparator used, and @entity117 . CONCLUSION: @entity32 are heterogeneous in increasing CV/renal risks. The low increased risk associated with @entity9213 is mainly vascular in origin.

title: The effect of COX-2-selective XXXX on the myocardial, vascular and renal risks: a systematic review.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['NSAIDs', 'Non-steroidal anti-inflammatory drugs']

entities_list: @entity13586 :: ('MESH:C116926', 'Chemical') :: ['rofecoxib']

entities_list: @entity12698 :: ('MESH:C105934', 'Chemical') :: ['celecoxib']

entities_list: @entity3522 :: ('MESH:D004008', 'Chemical') :: ['diclofenac']

entities_list: @entity5018 :: ('MESH:D007052', 'Chemical') :: ['ibuprofen']

entities_list: @entity117 :: ('MESH:D001241', 'Chemical') :: ['acetylsalicylic acid']

entities_list: @entity3352 :: ('MESH:D007213', 'Chemical') :: ['indomethacin']

entities_list: @entity1623 :: ('MESH:D009288', 'Chemical') :: ['naproxen']

entities_list: @entity9213 :: ('MESH:C065757', 'Chemical') :: ['meloxicam', 'Meloxicam']

answer: @entity9213 :: (MESH:C065757,Chemical) :: ['meloxicam']


abstract: BACKGROUND: Patterns of @entity272 in developing nations are changing as frequencies of non-communicable diseases continue to increase. Appraisal of the current status of the disease profile is of utmost importance for health planning and resource allocation. METHODS: A prospective analysis of 895 cases of outpatient consultation during the years 2005-2010 was conducted. RESULTS: The mean      standard deviation age of @entity1 was 31.1      19.1  years. Non- @entity24412 accounted for 80.9% of all cases. @entity484 / @entity1909 (27.0%), @entity110 /erythemas (11.0%), @entity364 (9.5%), @entity272 (8.9%), @entity12104 (8.2%), @entity66 (8.2%), @entity1800 (6.8%), and @entity5 and @entity272 (5.4%) represented the most common presentations. @entity483 was the most common type of eczema (29.8%) among @entity1 (odds ratio [OR] 1.53, 95% confidence interval [CI] 1.09-2.13; P  =  0.013), in whom @entity74 (OR 3.90, 95% CI 1.73-8.92; P  <  0.001) and @entity1800 (OR 1.80, 95% CI 1.09-3.25; P  =  0.021) were also frequent. Adults were more likely to be diagnosed with @entity203 (OR 3.58, 95% CI 1.09-11.80; P  =  0.003), @entity5 / @entity5 (OR 4.97, 95% CI 1.53-16.10; P  =  0.030), or @entity2597 (OR 8.13, 95% CI 1.09-60.20; P  =  0.015). Female subjects were significantly affected by @entity110 ( @entity17709 , 95% CI 1.00-2.33; P  =  0.030) and @entity12104 (OR 1.80, 95% CI 1.09-3.03; P  =  0.019). CONCLUSIONS: The present pattern shows that @entity24412 are predominant. Occurrences of @entity484 and @entity110 are increasing at similar rates, whereas @entity24412 are decreasing in frequency. Resources and research should be directed towards the prevention of @entity24412 at this time as the campaign for a cleaner environment continues.

title: Spectrum of XXXX presented at LAUTECH Teaching Hospital, Osogbo, southwest Nigeria.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity483 :: ('MESH:D003876', 'Disease') :: ['Atopic dermatitis']

entities_list: @entity2597 :: ('MESH:D003240', 'Disease') :: ['autoimmune connective tissue disorders']

entities_list: @entity12104 :: ('MESH:D017444', 'Disease') :: ['papulosquamous diseases']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['pigmentary diseases']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors', 'malignancy']

entities_list: @entity203 :: ('MESH:D003875', 'Disease') :: ['drug eruptions']

entities_list: @entity24412 :: ('MESH:D012874', 'Disease') :: ['infectious skin diseases', 'non-infectious skin diseases']

entities_list: @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal infections']

entities_list: @entity1800 :: ('MESH:D014777', 'Disease') :: ['viral infections']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['cornification disorders']

entities_list: @entity272 :: ('MESH:D012871', 'Disease') :: ['skin appendage disorders', 'malignant skin lesions', 'skin disease']

entities_list: @entity110 :: ('MESH:D014581', 'Disease') :: ['urticarias']

entities_list: @entity1909 :: ('MESH:D003872', 'Disease') :: ['dermatitis']

entities_list: @entity484 :: ('MESH:D004485', 'Disease') :: ['Eczemas', 'eczemas']

answer: @entity272 :: (MESH:D012871,Disease) :: ['skin diseases']


abstract: Staging in @entity263 , as in any other @entity5 has significant ramifications in management. Currently, @entity1486 ( @entity1486 ) determination and the bone scan are two important procedures in the pretreatment staging workup of @entity263 . @entity1486 is a very useful serum tumor marker in the management of @entity263 @entity1 . We retrospectively evaluated 90 @entity1 at the time of initial diagnosis of @entity263 , all of whom had initial @entity1486 levels measured, as well as bone scans obtained. In addition to the @entity1486 level, we considered clinical stage and pathologic grade in the prediction of bone scan for @entity3 , at the time of initial diagnosis of @entity263 . Negative predictive value for @entity1486 values < 10 ng/ml (27 @entity1 ), clinical stage A (9 @entity1 ) and pathologic grade 1 (19 @entity1 ) was 100%. The number of @entity1 with bone scan evidence of @entity3 with < 10 ng/ml and > 10 ng/ml @entity1486 levels were 0% (0/27 @entity1 ) and 27% (17/63 @entity1 ) (p = .0022 [Fisher's Exact test]; p = .003 [chi-square test]). In @entity1 with higher stage (p = .688), grade (p = .039), or @entity1486 levels (p = .0001), the incidence of bone @entity3 increased. However, none of these three parameters can predict reliably bone scan evidence of @entity3 (i.e., positive predictive value). The negative predictive values did not improve when a combination of the two or three of the above parameters were used.

title: Can XXXX levels predict bone scan evidence of @entity3 in newly diagnosed @entity263 ?

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis', 'metastases']

entities_list: @entity1486 :: ('354', 'Gene') :: ['PSA', 'prostate-specific antigen']

answer: @entity1486 :: (354,Gene) :: ['prostate-specific antigen']


abstract: Staging in @entity263 , as in any other @entity5 has significant ramifications in management. Currently, @entity1486 ( @entity1486 ) determination and the bone scan are two important procedures in the pretreatment staging workup of @entity263 . @entity1486 is a very useful serum tumor marker in the management of @entity263 @entity1 . We retrospectively evaluated 90 @entity1 at the time of initial diagnosis of @entity263 , all of whom had initial @entity1486 levels measured, as well as bone scans obtained. In addition to the @entity1486 level, we considered clinical stage and pathologic grade in the prediction of bone scan for @entity3 , at the time of initial diagnosis of @entity263 . Negative predictive value for @entity1486 values < 10 ng/ml (27 @entity1 ), clinical stage A (9 @entity1 ) and pathologic grade 1 (19 @entity1 ) was 100%. The number of @entity1 with bone scan evidence of @entity3 with < 10 ng/ml and > 10 ng/ml @entity1486 levels were 0% (0/27 @entity1 ) and 27% (17/63 @entity1 ) (p = .0022 [Fisher's Exact test]; p = .003 [chi-square test]). In @entity1 with higher stage (p = .688), grade (p = .039), or @entity1486 levels (p = .0001), the incidence of bone @entity3 increased. However, none of these three parameters can predict reliably bone scan evidence of @entity3 (i.e., positive predictive value). The negative predictive values did not improve when a combination of the two or three of the above parameters were used.

title: Can @entity1486 levels predict bone scan evidence of @entity3 in newly diagnosed XXXX ?

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: Staging in @entity263 , as in any other @entity5 has significant ramifications in management. Currently, @entity1486 ( @entity1486 ) determination and the bone scan are two important procedures in the pretreatment staging workup of @entity263 . @entity1486 is a very useful serum tumor marker in the management of @entity263 @entity1 . We retrospectively evaluated 90 @entity1 at the time of initial diagnosis of @entity263 , all of whom had initial @entity1486 levels measured, as well as bone scans obtained. In addition to the @entity1486 level, we considered clinical stage and pathologic grade in the prediction of bone scan for @entity3 , at the time of initial diagnosis of @entity263 . Negative predictive value for @entity1486 values < 10 ng/ml (27 @entity1 ), clinical stage A (9 @entity1 ) and pathologic grade 1 (19 @entity1 ) was 100%. The number of @entity1 with bone scan evidence of @entity3 with < 10 ng/ml and > 10 ng/ml @entity1486 levels were 0% (0/27 @entity1 ) and 27% (17/63 @entity1 ) (p = .0022 [Fisher's Exact test]; p = .003 [chi-square test]). In @entity1 with higher stage (p = .688), grade (p = .039), or @entity1486 levels (p = .0001), the incidence of bone @entity3 increased. However, none of these three parameters can predict reliably bone scan evidence of @entity3 (i.e., positive predictive value). The negative predictive values did not improve when a combination of the two or three of the above parameters were used.

title: Can @entity1486 levels predict bone scan evidence of XXXX in newly diagnosed @entity263 ?

answer: @entity3 :: (MESH:D009362,Disease) :: ['metastases']


abstract: UNASSIGNED: Gonadotroph pituitary @entity652 (GPAs) often present as invasive macroadenomas not amenable to complete surgical resection. Radiotherapy is the only post-operative option for @entity1 with large invasive or recurrent lesions. No medical treatment is available for these @entity1 . The somatostatin analogs (SSAs) octreotide and lanreotide that preferentially target @entity7931 ( @entity7931 ) have little effect on GPAs. It is widely accepted that the expression of specific SSTR subtypes determines the response to SSAs. Given that previous studies on mRNA and protein expression of SSTRs in GPAs have generated conflicting results, we investigated the expression of @entity7931 , @entity22260 , and @entity7932 (the main targets of available SSAs) in a clinically and pathologically well-characterized cohort of 108 @entity1 with GPAs. A total of 118 samples were examined by immunohistochemistry using validated and specific MABs. Matched primary and recurrent tissues were available for ten @entity1 . The results obtained were validated in an independent cohort of 27 GPAs. We observed that @entity22260 was significantly more abundant than @entity7931 (P<0.0001) in GPAs, while full-length @entity7932 was only expressed in few @entity5 . Expression of @entity22260 was similar in primary and recurrent @entity652 , was high in potentially aggressive lesions, and did not change significantly in @entity652 that recurred after irradiation. In conclusion, low levels of expression of @entity7931 may account for the limited response of GPAs to octreotide and lanreotide. Given the potent anti-proliferative, pro-apoptotic, and anti-angiogenic activities of @entity22260 , targeting this receptor with a multireceptor ligand SSA such as pasireotide may be indicated for potentially aggressive GPAs.

title: @entity22260 is a putative target for the medical treatment of gonadotroph XXXX of the pituitary.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity7931 :: ('6752', 'Gene') :: ['somatostatin receptor type 2', 'SSTR2']

entities_list: @entity652 :: ('MESH:D000236', 'Disease') :: ['adenomas']

answer: @entity652 :: (MESH:D000236,Disease) :: ['adenomas']


abstract: UNASSIGNED: Gonadotroph pituitary @entity652 (GPAs) often present as invasive macroadenomas not amenable to complete surgical resection. Radiotherapy is the only post-operative option for @entity1 with large invasive or recurrent lesions. No medical treatment is available for these @entity1 . The somatostatin analogs (SSAs) octreotide and lanreotide that preferentially target @entity7931 ( @entity7931 ) have little effect on GPAs. It is widely accepted that the expression of specific SSTR subtypes determines the response to SSAs. Given that previous studies on mRNA and protein expression of SSTRs in GPAs have generated conflicting results, we investigated the expression of @entity7931 , @entity22260 , and @entity7932 (the main targets of available SSAs) in a clinically and pathologically well-characterized cohort of 108 @entity1 with GPAs. A total of 118 samples were examined by immunohistochemistry using validated and specific MABs. Matched primary and recurrent tissues were available for ten @entity1 . The results obtained were validated in an independent cohort of 27 GPAs. We observed that @entity22260 was significantly more abundant than @entity7931 (P<0.0001) in GPAs, while full-length @entity7932 was only expressed in few @entity5 . Expression of @entity22260 was similar in primary and recurrent @entity652 , was high in potentially aggressive lesions, and did not change significantly in @entity652 that recurred after irradiation. In conclusion, low levels of expression of @entity7931 may account for the limited response of GPAs to octreotide and lanreotide. Given the potent anti-proliferative, pro-apoptotic, and anti-angiogenic activities of @entity22260 , targeting this receptor with a multireceptor ligand SSA such as pasireotide may be indicated for potentially aggressive GPAs.

title: XXXX is a putative target for the medical treatment of gonadotroph @entity652 of the pituitary.

answer: @entity22260 :: (6753,Gene) :: ['SSTR3']


abstract: The aim of this study is to present our preliminary experience in treating BPH-related urine retention, resistant to other medical treatment, with transurethral brachytherapy. We also deal with dosimetric analysis so as to eliminate ethical concerns about the exposure of @entity1 not suffering from @entity5 to a certain level of body irradiation. @entity1 suffering from BPH-related @entity11044 were treated with two transurethral applications (three weeks apart) of Cs137 MDR, which delivered a total of 16 Gy, at 0.5 cm from the urethral walls (dose rate 5-7 Gy/h). The application was done under ultrasonographic observation. Dosimetric calculation of the radiation exposure of the @entity1 body during transurethral radiotherapy (TURT) was performed for @entity1 suffering from @entity263 and treated with external beam radiotherapy and a boost dose through transurethral brachytherapy. For this purpose we used TLDs on skin surface and dosimetric analysis of X-ray films. Five @entity1 treated for @entity11044 presented no sign of acute @entity137 . All of them were weaned of their indwelling catheter immediately after the end of the first application. Obstruction did not recur within 12-18 months of follow-up. The dose delivered outside the prostate ranges from 1-7 cG, depending upon location. Proximal rectal and bladder walls received 1-2 Gy, a dose that is far from inducing acute or late @entity137 . The estimated risk for @entity105 is negligible, and the expected benefit for the quality of life transcends the risks. No ethical concern is justified for testing transurethral radiotherapy for BPH-related @entity11044 . TURT seems to be effective and provides durable results. Further investigation is required.

title: Transurethral radiotherapy for benign prostatic hypertrophy-related XXXX . Dosimetry, ethics, and preliminary results.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis']

entities_list: @entity11044 :: ('MESH:D014524', 'Disease') :: ['BPH urethral obstruction', 'urethral obstruction']

answer: @entity11044 :: (MESH:D014524,Disease) :: ['urethral obstruction']


abstract: One of the main features of systemic and localized forms of @entity2631 is @entity1504 , the mechanism of which is not yet understood. Recently, we have shown undetectable or decreased expression of complement regulatory molecules, @entity806 ( @entity806 ) and @entity9819 ( @entity9819 ), in cutaneous endothelium of @entity1 with @entity785 ( @entity785 ). In some @entity1 , @entity1009 expression in endothelium was also altered. As these molecules protect endothelial cells from damage by autologous complement, their decreased expression could be part of the mechanism of @entity1504 in @entity785 . In the present study, we investigated the expression of @entity806 , @entity9819 and @entity1009 in the endothelium of lesional and non-lesional skin of @entity1 with localized morphoea. Normal skin and lesional skin from @entity1 with @entity1252 , and three @entity32 , were included as relevant controls. The results showed that the extent of expression of the three molecules in non-lesional skin of @entity1 with morphoea, on all the skin cells and structures, was identical to that of normal skin. In lesional skin, however, the expression of @entity806 and @entity9819 in endothelium was either undetectable or only present to a very slight degree. @entity1009 expression in endothelium in lesional skin was normal. No such aberrant expression was observed in the lesions of any of the control diseases. These results indicate a decreased ability of endothelial cells in lesional areas to protect themselves from autologous complement, and this could contribute to @entity1504 in @entity75 .

title: XXXX are associated with aberrant expression of @entity806 and decay accelerating factor in vascular endothelium.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammatory diseases']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['morphoea lesions']

entities_list: @entity1252 :: ('MESH:D008180', 'Disease') :: ['systemic lupus erythematosus']

entities_list: @entity2631 :: ('MESH:D012594', 'Disease') :: ['scleroderma']

entities_list: @entity1504 :: ('MESH:D002561', 'Disease') :: ['vascular damage']

entities_list: @entity806 :: ('4179', 'Gene') :: ['MCP', 'membrane cofactor protein']

entities_list: @entity9819 :: ('1604', 'Gene') :: ['DAF', 'decay-accelerating factor']

entities_list: @entity785 :: ('MESH:D012595', 'Disease') :: ['SSc', 'systemic sclerosis']

answer: @entity75 :: (MESH:D001927,Disease) :: ['Morphoea lesions']


abstract: One of the main features of systemic and localized forms of @entity2631 is @entity1504 , the mechanism of which is not yet understood. Recently, we have shown undetectable or decreased expression of complement regulatory molecules, @entity806 ( @entity806 ) and @entity9819 ( @entity9819 ), in cutaneous endothelium of @entity1 with @entity785 ( @entity785 ). In some @entity1 , @entity1009 expression in endothelium was also altered. As these molecules protect endothelial cells from damage by autologous complement, their decreased expression could be part of the mechanism of @entity1504 in @entity785 . In the present study, we investigated the expression of @entity806 , @entity9819 and @entity1009 in the endothelium of lesional and non-lesional skin of @entity1 with localized morphoea. Normal skin and lesional skin from @entity1 with @entity1252 , and three @entity32 , were included as relevant controls. The results showed that the extent of expression of the three molecules in non-lesional skin of @entity1 with morphoea, on all the skin cells and structures, was identical to that of normal skin. In lesional skin, however, the expression of @entity806 and @entity9819 in endothelium was either undetectable or only present to a very slight degree. @entity1009 expression in endothelium in lesional skin was normal. No such aberrant expression was observed in the lesions of any of the control diseases. These results indicate a decreased ability of endothelial cells in lesional areas to protect themselves from autologous complement, and this could contribute to @entity1504 in @entity75 .

title: @entity75 are associated with aberrant expression of XXXX and decay accelerating factor in vascular endothelium.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

answer: @entity806 :: (4179,Gene) :: ['membrane cofactor protein']


abstract: OBJECTIVE: To describe the first reported successful use of adjunctive linezolid bladder irrigation. CASE SUMMARY: An 89-year-old @entity1 with 10% TBSA burns developed @entity810 . She acquired a @entity293 caused by @entity2176 -resistant @entity6375 (VREfm). Based on clinical status, a linezolid bladder irrigation was initiated in addition to high-dose intravenous linezolid and demonstrated microbiological cure with 7 days of treatment. DISCUSSION: Linezolid is primarily hepatically cleared and has no labeled indication for @entity293 . @entity1696 adds an additional complication of potentially reduced urinary drug concentrations. Bladder irrigation offers the benefit of achieving high local drug concentrations, but there are no data regarding such a route for linezolid. This case report is the first demonstrating the use, stability, safety, and efficacy of @entity5136 as a continuous bladder irrigation. CONCLUSIONS: Linezolid use as a bladder irrigation may be a feasible route of administration in anuric, critically ill @entity1 with VREfm and few antimicrobial options. Further studies are warranted.

title: Linezolid Bladder Irrigation as Adjunctive Treatment for a XXXX -Resistant @entity6375 Catheter-Associated Urinary Tract Infection: A Case Report.

entities_list: @entity1 :: ('9606', 'Species') :: ['woman', 'patients']

entities_list: @entity2176 :: ('MESH:D014640', 'Chemical') :: ['vancomycin']

entities_list: @entity6375 :: ('1352', 'Species') :: ['Enterococcus faecium']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['septic shock and anuric acute kidney insufficiency']

entities_list: @entity5136 :: ('MESH:C098010', 'Chemical') :: ['linezolid']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infection', 'urinary tract infections']

answer: @entity2176 :: (MESH:D014640,Chemical) :: ['Vancomycin']


abstract: OBJECTIVE: To describe the first reported successful use of adjunctive linezolid bladder irrigation. CASE SUMMARY: An 89-year-old @entity1 with 10% TBSA burns developed @entity810 . She acquired a @entity293 caused by @entity2176 -resistant @entity6375 (VREfm). Based on clinical status, a linezolid bladder irrigation was initiated in addition to high-dose intravenous linezolid and demonstrated microbiological cure with 7 days of treatment. DISCUSSION: Linezolid is primarily hepatically cleared and has no labeled indication for @entity293 . @entity1696 adds an additional complication of potentially reduced urinary drug concentrations. Bladder irrigation offers the benefit of achieving high local drug concentrations, but there are no data regarding such a route for linezolid. This case report is the first demonstrating the use, stability, safety, and efficacy of @entity5136 as a continuous bladder irrigation. CONCLUSIONS: Linezolid use as a bladder irrigation may be a feasible route of administration in anuric, critically ill @entity1 with VREfm and few antimicrobial options. Further studies are warranted.

title: Linezolid Bladder Irrigation as Adjunctive Treatment for a @entity2176 -Resistant XXXX Catheter-Associated Urinary Tract Infection: A Case Report.

answer: @entity6375 :: (1352,Species) :: ['Enterococcus faecium']


abstract: OBJECTIVE: The aim of this study was to investigate the presence and correlates of clinically relevant @entity73 in middle-aged adults with childhood-onset @entity1723 ( @entity1723 ). RESEARCH DESIGN AND METHODS: During 2010-2013, 97 adults diagnosed with @entity1723 and aged <18 years (age and duration 49    7 and 41    6 years, respectively; 51% female) and 138 similarly aged adults without @entity1723 (age 49    7 years; 55% female) completed extensive neuropsychological testing. Biomedical data on @entity1 with @entity1723 were collected periodically from 1986-1988. @entity73 status was based on the number of test scores >= 1.5 SD worse than demographically appropriate published norms: none, mild (only one test), or clinically relevant (two or more tests). RESULTS: The prevalence of clinically relevant @entity73 was five times higher among @entity1 with than without @entity1723 (28% vs. 5%; P < 0.0001), independent of education, age, or blood pressure. Effect sizes were large (Cohen d 0.6-0.9; P < 0.0001) for psychomotor speed and visuoconstruction tasks, and were modest (d 0.3-0.6; P < 0.05) for measures of executive function. Among @entity1 with @entity1723 , prevalent @entity73 was related to 14-year average A1c >7.5%/58 mmol/mol (odds ratio [OR] 3.0; P = 0.009), @entity989 (OR 2.8; P = 0.01), and distal symmetric @entity305 (OR 2.6; P = 0.03) measured 5 years earlier; higher BMI (OR 1.1; P = 0.03); and ankle-brachial index >= 1.3 (OR 4.2; P = 0.01) measured 20 years earlier, independent of education. CONCLUSION: Clinically relevant @entity73 is highly prevalent among these middle-aged adults with childhood-onset @entity1723 . In this aging cohort, chronic @entity4854 and prevalent @entity66 were associated with @entity73 , relationships shown previously in younger populations with @entity1723 . Two additional potentially modifiable risk factors for @entity1723 -related @entity73 , vascular health and BMI, deserve further study.

title: Clinically Relevant XXXX in Middle-Aged Adults With Childhood-Onset Type 1 Diabetes.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['microvascular disease']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive impairment', 'Cognitive impairment']

entities_list: @entity305 :: ('MESH:D011115', 'Disease') :: ['polyneuropathy']

entities_list: @entity1723 :: ('MESH:D003922', 'Disease') :: ['T1D', 'type 1 diabetes']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['proliferative retinopathy']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

answer: @entity73 :: (MESH:D003072,Disease) :: ['Cognitive Impairment']


abstract: Between 1957 and 1981, 49,904 @entity1 with @entity5 were registered at the Birmingham Cancer Registry. The annual incidence was 24.5 per 100,000 population for @entity694 and 18.4 per 100,000 for that of the rectum. The annual number of @entity1 increased by 41.9 per cent. The age-adjusted 5-year survival rate was 26.4 per cent for @entity694 and 28.2 per cent for @entity5 . Between 1977 and 1981 these rates increased significantly to 30.3 and 30.0 per cent respectively (P < 0.01). Stage for stage, @entity694 was associated with longer survival than that of the rectum. Curative and palliative resection rates increased, especially for anterior resection. The operative mortality rate remained constant at 8 per cent. Despite increases in palliative resection rates 50 per cent of these @entity1 required a stoma. Treatment was not undertaken in 37.4 per cent of @entity1 . The end results of treatment are little better than those reported previously from this registry.

title: XXXX in the West Midlands, 1957-1981.

entities_list: @entity694 :: ('MESH:D003110', 'Disease') :: ['colonic cancer', 'colonic carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['large bowel cancer', 'rectal cancer']

answer: @entity694 :: (MESH:D003110,Disease) :: ['Cancer of the colon and rectum']


abstract: OBJECTIVES: Hyperthermic intraperitoneal chemotherapy (HIPEC) is an intriguing method of delivery wherein the cytotoxic agent is continuously heated and circulated throughout the peritoneum in an attempt to bolster drug efficacy. Despite HIPEC's potential, ascertaining the optimal dose without compromising @entity1 tolerability remains indeterminate. METHODS: We retrospectively evaluated 52 @entity43 @entity1 who were treated with consolidation HIPEC with @entity3003 at varying doses (e.g., AUC 6, 8 or 10) subsequent to optimal debulking surgery and the attainment of a clinical complete response to their primary chemotherapy regimen. The following @entity1 and operative characteristics were abstracted: demographics, surgery and pathology data, chemotherapy regimen, intraoperative results, @entity137 , @entity260 , length of hospital stay and survival data. RESULTS: Twelve @entity1 received HIPEC @entity3003 at an AUC 6, 15 subjects were treated with @entity3003 at an AUC 8 and 25 underwent @entity3003 at an AUC 10. There were no intraoperative complications during the administration of HIPEC; mean estimated @entity190 was 50  mL and length of hospital stay was 1.65  days. In the overall study population, 5 @entity1 developed grade 3/4 @entity417 and 33 subjects exhibited grade  <=2 @entity882 and @entity1398 . Thirteen @entity1 also developed grade  <=2 @entity390 on postoperative day 1, which was successfully addressed with anti-emetic therapy; there were no hospital readmissions. CONCLUSIONS: The results from the current evaluation suggest that consolidation hyperthermic intraperitoneal chemotherapy with @entity3003 is both feasible and reasonably tolerated, even at an AUC of 10. However, additional, randomized study of this procedure incorporating chemotherapy dose escalation with a more extensive @entity1 population is warranted.

title: The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with XXXX in the treatment of @entity43 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity43 :: ('MESH:D010051', 'Disease') :: ['advanced stage ovarian cancer']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity190 :: ('MESH:D006473', 'Disease') :: ['blood loss']

entities_list: @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

answer: @entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']


abstract: OBJECTIVES: Hyperthermic intraperitoneal chemotherapy (HIPEC) is an intriguing method of delivery wherein the cytotoxic agent is continuously heated and circulated throughout the peritoneum in an attempt to bolster drug efficacy. Despite HIPEC's potential, ascertaining the optimal dose without compromising @entity1 tolerability remains indeterminate. METHODS: We retrospectively evaluated 52 @entity43 @entity1 who were treated with consolidation HIPEC with @entity3003 at varying doses (e.g., AUC 6, 8 or 10) subsequent to optimal debulking surgery and the attainment of a clinical complete response to their primary chemotherapy regimen. The following @entity1 and operative characteristics were abstracted: demographics, surgery and pathology data, chemotherapy regimen, intraoperative results, @entity137 , @entity260 , length of hospital stay and survival data. RESULTS: Twelve @entity1 received HIPEC @entity3003 at an AUC 6, 15 subjects were treated with @entity3003 at an AUC 8 and 25 underwent @entity3003 at an AUC 10. There were no intraoperative complications during the administration of HIPEC; mean estimated @entity190 was 50  mL and length of hospital stay was 1.65  days. In the overall study population, 5 @entity1 developed grade 3/4 @entity417 and 33 subjects exhibited grade  <=2 @entity882 and @entity1398 . Thirteen @entity1 also developed grade  <=2 @entity390 on postoperative day 1, which was successfully addressed with anti-emetic therapy; there were no hospital readmissions. CONCLUSIONS: The results from the current evaluation suggest that consolidation hyperthermic intraperitoneal chemotherapy with @entity3003 is both feasible and reasonably tolerated, even at an AUC of 10. However, additional, randomized study of this procedure incorporating chemotherapy dose escalation with a more extensive @entity1 population is warranted.

title: The feasibility of administering varying high-dose consolidation hyperthermic intraperitoneal chemotherapy with @entity3003 in the treatment of XXXX .

answer: @entity43 :: (MESH:D010051,Disease) :: ['ovarian carcinoma']


abstract: We recently demonstrated that reactive astrocytes express @entity1110 diaphorase activity, a marker for @entity842 Synthase, following transient global @entity63 (Neuroscience Letters 154: 125-128). There has been little evidence that astrocytes express @entity842 Synthase or produce NO ( @entity842 ) in vivo; although in vitro experiments have shown that cultured astrocytes can produce NO. To determine whether reactive astrocytes express inducible form of NOS ( @entity1506 ) in vivo, we studied the pathological changes of @entity35 hippocampus by immunohistochemistry after 10 minutes of transient global @entity63 , which results in the selective delayed death of @entity1249 pyramidal cells and marked @entity5219 in the @entity1249 subfield. In the normal hippocampus, astrocytes express neither @entity1110 diaphorase activity nor @entity1506 . After @entity63 , the temporal and spatial pattern of @entity1506 , @entity1110 diaphorase, and @entity40 are very similar, indicating that reactive astrocytes express @entity1506 . Double staining for @entity1110 diaphorase and @entity40 , or @entity1506 and @entity40 confirmed that reactive astrocytes express both @entity1110 diaphorase activity and @entity1506 immunoreactivity. These changes were observed three day after @entity63 and increased in prominence from one week to one month. The staining pattern of OX42, an antibody that recognizes both microglia and macrophages, is spatially and temporally distinct from the pattern of @entity1110 diaphorase and @entity1506 staining. Thus, we conclude that transient global @entity63 induces @entity1506 primarily in reactive astrocytes. This increase in NOS expression and, presumably, NO production by reactive astrocytes may play a role in the process of delayed @entity528 or in the remodeling responses that occur after @entity2806 .

title: Expression of the inducible form of @entity842 synthase by reactive astrocytes after transient global XXXX .

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['ischemic damage']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['Nitric Oxide', 'nitric oxide']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['neuronal death']

answer: @entity63 :: (MESH:D007511,Disease) :: ['ischemia']


abstract: We recently demonstrated that reactive astrocytes express @entity1110 diaphorase activity, a marker for @entity842 Synthase, following transient global @entity63 (Neuroscience Letters 154: 125-128). There has been little evidence that astrocytes express @entity842 Synthase or produce NO ( @entity842 ) in vivo; although in vitro experiments have shown that cultured astrocytes can produce NO. To determine whether reactive astrocytes express inducible form of NOS ( @entity1506 ) in vivo, we studied the pathological changes of @entity35 hippocampus by immunohistochemistry after 10 minutes of transient global @entity63 , which results in the selective delayed death of @entity1249 pyramidal cells and marked @entity5219 in the @entity1249 subfield. In the normal hippocampus, astrocytes express neither @entity1110 diaphorase activity nor @entity1506 . After @entity63 , the temporal and spatial pattern of @entity1506 , @entity1110 diaphorase, and @entity40 are very similar, indicating that reactive astrocytes express @entity1506 . Double staining for @entity1110 diaphorase and @entity40 , or @entity1506 and @entity40 confirmed that reactive astrocytes express both @entity1110 diaphorase activity and @entity1506 immunoreactivity. These changes were observed three day after @entity63 and increased in prominence from one week to one month. The staining pattern of OX42, an antibody that recognizes both microglia and macrophages, is spatially and temporally distinct from the pattern of @entity1110 diaphorase and @entity1506 staining. Thus, we conclude that transient global @entity63 induces @entity1506 primarily in reactive astrocytes. This increase in NOS expression and, presumably, NO production by reactive astrocytes may play a role in the process of delayed @entity528 or in the remodeling responses that occur after @entity2806 .

title: Expression of the inducible form of XXXX synthase by reactive astrocytes after transient global @entity63 .

answer: @entity842 :: (MESH:D009569,Chemical) :: ['nitric oxide']


abstract: As first reported by our group in 1975, severe @entity712 due to @entity1000 could be improved in @entity1 receiving beta-blocker therapy starting at a very low dose and followed by a stepwise increase. Since then, these results have been confirmed by our own group and by others, and similar results were also obtained in @entity1 with other forms of @entity296 , including @entity296 . In 13 separate studies involving a total of 651 @entity1 with @entity1000 , beta-blockade for 2 to 19 months (in addition to conventional treatment of @entity712 , including @entity1289 inhibitor therapy), significantly improved cardiac function. These studies were performed using @entity1406 , @entity29393 , @entity6555 and @entity6310 . Eight studies investigated the effects of long term beta-blocker treatment in @entity1 with @entity712 and @entity296 due to @entity453 , @entity340 , @entity6 and @entity632 therapy. A total of 128 @entity1 were treated with @entity1406 , @entity1405 or @entity29393 for periods of 2 to 12 months. All studies reported a significant improvement in cardiac function. Three studies reported results on survival and the need for cardiac transplantation. The first study published by our group reported improved survival in @entity1 with @entity1000 treated with @entity1406 plus digitalis and diuretics compared with a matched control group.(ABSTRACT TRUNCATED AT 250 WORDS)

title: The role of beta-blockers in the treatment of XXXX and @entity712 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity1289 :: ('1636', 'Gene') :: ['angiotensin converting enzyme']

entities_list: @entity296 :: ('MESH:D009202', 'Disease') :: ['cardiomyopathy', 'ischaemic cardiomyopathy']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity6555 :: ('MESH:D007741', 'Chemical') :: ['labetalol']

entities_list: @entity1405 :: ('MESH:C043211', 'Chemical') :: ['carvedilol']

entities_list: @entity1406 :: ('MESH:D008790', 'Chemical') :: ['metoprolol']

entities_list: @entity1000 :: ('MESH:C536277', 'Disease') :: ['idiopathic dilated cardiomyopathy']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity6310 :: ('MESH:D011217', 'Chemical') :: ['practolol']

entities_list: @entity29393 :: ('MESH:C024307', 'Chemical') :: ['bucindolol']

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['valvular heart disease']

answer: @entity296 :: (MESH:D009202,Disease) :: ['cardiomyopathy']


abstract: As first reported by our group in 1975, severe @entity712 due to @entity1000 could be improved in @entity1 receiving beta-blocker therapy starting at a very low dose and followed by a stepwise increase. Since then, these results have been confirmed by our own group and by others, and similar results were also obtained in @entity1 with other forms of @entity296 , including @entity296 . In 13 separate studies involving a total of 651 @entity1 with @entity1000 , beta-blockade for 2 to 19 months (in addition to conventional treatment of @entity712 , including @entity1289 inhibitor therapy), significantly improved cardiac function. These studies were performed using @entity1406 , @entity29393 , @entity6555 and @entity6310 . Eight studies investigated the effects of long term beta-blocker treatment in @entity1 with @entity712 and @entity296 due to @entity453 , @entity340 , @entity6 and @entity632 therapy. A total of 128 @entity1 were treated with @entity1406 , @entity1405 or @entity29393 for periods of 2 to 12 months. All studies reported a significant improvement in cardiac function. Three studies reported results on survival and the need for cardiac transplantation. The first study published by our group reported improved survival in @entity1 with @entity1000 treated with @entity1406 plus digitalis and diuretics compared with a matched control group.(ABSTRACT TRUNCATED AT 250 WORDS)

title: The role of beta-blockers in the treatment of @entity296 and XXXX .

answer: @entity712 :: (MESH:D006333,Disease) :: ['ischaemic heart failure']


abstract: BACKGROUND AND AIM: Glycated hemoglobin (HbA1c) assessment is basic to @entity6 management. Little is done to describe the whole spectrum of the trajectory, its related temporal patterns of metabolic indices, and comorbidities. METHODS AND RESULTS: This was a longitudinal study. In the @entity6 Management through Integrated Delivery System project in Taiwan, enrollees had @entity6 , but no major comorbidities. They were randomized into intensive or conventional education (health, diet and exercise) groups. HbA1c was classified by a groupbased trajectory model on the basis of repeated six-monthly measurements. We analyzed data from 1091 subjects who had at least two measurements on HbA1c. HbA1c exhibited three distinct ranges of low (42-53 mmol/mol), intermediate (64-75 mmol/mol) and high (97 mmol/mol), all of which persisted for 4.5 years regardless of receiving intensive education or not. Temporal changes and a time-group interaction were found for @entity1674 , total @entity165 , HDL-C and LDL-C. The high trajectory was associated with the major co-morbidities of @entity989 , @entity8 , @entity16 , @entity64 , @entity4053 , and @entity1270 . @entity1 in the intensive education group (62.4%), which were equally distributed in the three trajectories, had significantly lower @entity4051 cs (-0.14%= -1.5 mmol/mol, p=0.026). The intermediate trajectory @entity1 with intensive education had @entity4051 cs higher than the low trajectory @entity1 with conventional education (b=0.189, p=0.033). Though not significant, a similar pattern was found for @entity3918 education in the high group (b=0.223, p=0.154). CONCLUSIONS: Novel strategies beyond current education and pharmacotherapeutic regimens are needed to lower HbA1c at least 11 mmol/mol for the high HbA1c group to minimize comorbidities.

title: Management trajectories in the type 2 XXXX Integrated Delivery System project in Taiwan: accounting for behavioral therapy, nutrition education and therapeutics.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['Diabetes', 'diabetes']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity4053 :: ('MESH:D007003', 'Disease') :: ['hypoglycemia']

entities_list: @entity1270 :: ('MESH:D007662', 'Disease') :: ['ketoacidosis']

entities_list: @entity989 :: ('MESH:D012164', 'Disease') :: ['retinopathy']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes']


abstract: UNASSIGNED: @entity1760 ( @entity1025 ) is an essential ion to the @entity1 body, playing an instrumental role in supporting and sustaining health and life. As the second most abundant intracellular cation after @entity972 , it is involved in over 600 enzymatic reactions including energy metabolism and protein synthesis. Although @entity1025 availability has been proven to be disturbed during several clinical situations, serum @entity1025 values are not generally determined in @entity1 . This review aims to provide an overview of the function of @entity1025 in @entity1 health and disease. In short, @entity1025 plays an important physiological role particularly in the brain, heart, and skeletal muscles. Moreover, @entity1025 supplementation has been shown to be beneficial in treatment of, among others, @entity1468 , @entity2704 , @entity308 , @entity453 , and @entity565 . Over the last decade, several hereditary forms of @entity1272 have been deciphered, including mutations in @entity31566 ( @entity31566 ), @entity23631 , and @entity57449 ( @entity57449 ). Recently, mutations in @entity1025 transporter 1 ( @entity23996 ) were linked to @entity784 underlining the important role of @entity1025 in cell viability. Moreover, @entity1272 can be the consequence of the use of certain types of drugs, such as diuretics, epidermal growth factor receptor inhibitors, calcineurin inhibitors, and proton pump inhibitors. This review provides an extensive and comprehensive overview of @entity1025 research over the last few decades, focusing on the regulation of @entity1025 homeostasis in the intestine, kidney, and bone and disturbances which may result in @entity1272 .

title: XXXX in @entity1 : Implications for Health and Disease.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity31566 :: ('140803', 'Gene') :: ['TRPM6', 'transient receptor potential melastatin type 6']

entities_list: @entity1272 :: ('MESH:C537153', 'Disease') :: ['hypomagnesemia']

entities_list: @entity784 :: ('MESH:D016399', 'Disease') :: ['T-cell deficiency']

entities_list: @entity1468 :: ('MESH:D011225', 'Disease') :: ['preeclampsia']

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

entities_list: @entity1760 :: ('MESH:D008274', 'Chemical') :: ['Magnesium']

answer: @entity1760 :: (MESH:D008274,Chemical) :: ['Magnesium']


abstract: UNASSIGNED: @entity1760 ( @entity1025 ) is an essential ion to the @entity1 body, playing an instrumental role in supporting and sustaining health and life. As the second most abundant intracellular cation after @entity972 , it is involved in over 600 enzymatic reactions including energy metabolism and protein synthesis. Although @entity1025 availability has been proven to be disturbed during several clinical situations, serum @entity1025 values are not generally determined in @entity1 . This review aims to provide an overview of the function of @entity1025 in @entity1 health and disease. In short, @entity1025 plays an important physiological role particularly in the brain, heart, and skeletal muscles. Moreover, @entity1025 supplementation has been shown to be beneficial in treatment of, among others, @entity1468 , @entity2704 , @entity308 , @entity453 , and @entity565 . Over the last decade, several hereditary forms of @entity1272 have been deciphered, including mutations in @entity31566 ( @entity31566 ), @entity23631 , and @entity57449 ( @entity57449 ). Recently, mutations in @entity1025 transporter 1 ( @entity23996 ) were linked to @entity784 underlining the important role of @entity1025 in cell viability. Moreover, @entity1272 can be the consequence of the use of certain types of drugs, such as diuretics, epidermal growth factor receptor inhibitors, calcineurin inhibitors, and proton pump inhibitors. This review provides an extensive and comprehensive overview of @entity1025 research over the last few decades, focusing on the regulation of @entity1025 homeostasis in the intestine, kidney, and bone and disturbances which may result in @entity1272 .

title: @entity1760 in XXXX : Implications for Health and Disease.

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

answer: @entity1 :: (9606,Species) :: ['Man']


abstract: BACKGROUND/AIMS: The integrin family of adhesion molecules on intestinal lamina propria mononuclear cells (LPMNC) was studied using fluorescence-activated cell cytometry. These molecules are implicated in extravascular cell migration and are important regulators of disease. METHODS: Using fluorescence-activated cell cytometry, B- and T-cell subsets in the intestines of 10 normal @entity1 , 11 @entity1 with @entity30 , and 8 @entity1 with @entity31 were stained with monoclonal antibodies to a panel of integrins. RESULTS: Expression of alpha integrins on CD3+ T cells and @entity1075 + B cells was different in normal and @entity29 LPMNC. @entity31 T cells expressed less @entity10483 and significantly more alpha 2 and alpha 6. There was a difference in @entity1293 expression between LPMNC B cells from @entity30 and normal intestines. Sixteen percent of @entity1075 + LPMNC B cells from Crohn's and 19% of @entity31 LPMNC expressed alpha 2. @entity31 @entity1075 + LPMNC B cells expressed more alpha 5 integrin than normal specimens. CD3+ T cells and @entity1075 + B cells expressed alpha 6 only in @entity31 . @entity31 and @entity30 @entity1075 + LPMNC expressed less @entity1293 , consistent with their reciprocal increases of alpha 5 and alpha 2. A difference in beta 7 (Peyer's patch specific) antigen was observed between @entity29 and normal LPMNC for both CD3+ and @entity1075 + LPMNC. CONCLUSIONS: These findings identify the differences of lymphocyte homing capability in @entity29 and normal intestine.

title: @entity30 , XXXX , and normal intestinal lymphocytes express integrins in dissimilar patterns.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis', 'Ulcerative colitis', "Crohn's and ulcerative colitis"]

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]

answer: @entity31 :: (MESH:D003093,Disease) :: ['ulcerative colitis']


abstract: BACKGROUND/AIMS: The integrin family of adhesion molecules on intestinal lamina propria mononuclear cells (LPMNC) was studied using fluorescence-activated cell cytometry. These molecules are implicated in extravascular cell migration and are important regulators of disease. METHODS: Using fluorescence-activated cell cytometry, B- and T-cell subsets in the intestines of 10 normal @entity1 , 11 @entity1 with @entity30 , and 8 @entity1 with @entity31 were stained with monoclonal antibodies to a panel of integrins. RESULTS: Expression of alpha integrins on CD3+ T cells and @entity1075 + B cells was different in normal and @entity29 LPMNC. @entity31 T cells expressed less @entity10483 and significantly more alpha 2 and alpha 6. There was a difference in @entity1293 expression between LPMNC B cells from @entity30 and normal intestines. Sixteen percent of @entity1075 + LPMNC B cells from Crohn's and 19% of @entity31 LPMNC expressed alpha 2. @entity31 @entity1075 + LPMNC B cells expressed more alpha 5 integrin than normal specimens. CD3+ T cells and @entity1075 + B cells expressed alpha 6 only in @entity31 . @entity31 and @entity30 @entity1075 + LPMNC expressed less @entity1293 , consistent with their reciprocal increases of alpha 5 and alpha 2. A difference in beta 7 (Peyer's patch specific) antigen was observed between @entity29 and normal LPMNC for both CD3+ and @entity1075 + LPMNC. CONCLUSIONS: These findings identify the differences of lymphocyte homing capability in @entity29 and normal intestine.

title: XXXX , @entity31 , and normal intestinal lymphocytes express integrins in dissimilar patterns.

answer: @entity30 :: (MESH:D003424,Disease) :: ['Crohn's disease']


abstract: PURPOSE: Serum @entity1486 (PSA) levels following @entity263 are increasingly recognized as the most sensitive means to monitor disease status. However, beyond general agreement that @entity1 fare poorly when posttreatment PSA levels fail to normalize, many questions relative to postirradiation PSA remain unanswered. This study evaluates the potential prognostic value of postirradiation PSA in a large cohort of @entity1 followed with serial PSA determinations. METHODS AND MATERIALS: We analyzed disease outcome in 427 @entity1 with clinical stages T1 (122 @entity1 ), T2 (147 @entity1 ), T3 (152 @entity1 ), and T4 (six @entity1 ) @entity263 receiving definitive external radiation as sole therapy and followed for times ranging from 9-73 months (median 30 months) with a total of 2260 posttreatment PSA values. RESULTS: Excluding three @entity1 who died due to intercurrent illness without a posttreatment PSA, postirradiation PSA fell in 416 of 424 @entity1 (98%). @entity1486 levels continued to fall for up to 12 months but there was no evidence of significant declines beyond that. The time to nadir PSA was: 3 months, 60 @entity1 ; 6 months, 68 @entity1 , 9 months 148 @entity1 ; 12 months, 144 @entity1 . Time to nadir was not a significant determinant of outcome. @entity1486 levels at 3 and 6 months and the nadir level were individually highly correlated with outcome. In multivariate analyses of posttreatment values, only the nadir value was independently significant, with increasing relapse rates as its value was higher. It retained significance when pretreatment PSA level was included in the model. Nadir values ranged from undetectable (52 @entity1 ) to 20.3 ng/ml with a median of 1.1 ng/ml. Nadir values down to 1 ng/ml were prognostic; below 1 ng/ml (182 @entity1 ) the nadir value no longer yielded prognostic information additional to that inherent in the pretreatment value. Only @entity1 with nadir levels < 1 ng/ml fared well (5-year incidence of relapse or rising PSA 17%); however, if the pretreatment level exceeded 30 ng/ml, then even a nadir level < 1 ng/ml was associated with a 40% failure rate at 5 years. CONCLUSION: The nadir PSA value after radiation is a significant posttreatment determinant of outcome and was second only to the pretreatment value. Surprisingly low nadir values were prognostically significant. Only @entity1 whose nadir falls below 1 ng/ml can be said to have achieved a biochemical complete remission. However, even such low nadir values do not portend durable disease control for @entity1 with high pretreatment PSA levels.

title: Serum XXXX after radiation therapy for clinically localized @entity263 : prognostic implications.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'definitive radiation for prostate cancer']

entities_list: @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen', 'Prostate-specific antigen']

answer: @entity1486 :: (354,Gene) :: ['prostate-specific antigen']


abstract: PURPOSE: Serum @entity1486 (PSA) levels following @entity263 are increasingly recognized as the most sensitive means to monitor disease status. However, beyond general agreement that @entity1 fare poorly when posttreatment PSA levels fail to normalize, many questions relative to postirradiation PSA remain unanswered. This study evaluates the potential prognostic value of postirradiation PSA in a large cohort of @entity1 followed with serial PSA determinations. METHODS AND MATERIALS: We analyzed disease outcome in 427 @entity1 with clinical stages T1 (122 @entity1 ), T2 (147 @entity1 ), T3 (152 @entity1 ), and T4 (six @entity1 ) @entity263 receiving definitive external radiation as sole therapy and followed for times ranging from 9-73 months (median 30 months) with a total of 2260 posttreatment PSA values. RESULTS: Excluding three @entity1 who died due to intercurrent illness without a posttreatment PSA, postirradiation PSA fell in 416 of 424 @entity1 (98%). @entity1486 levels continued to fall for up to 12 months but there was no evidence of significant declines beyond that. The time to nadir PSA was: 3 months, 60 @entity1 ; 6 months, 68 @entity1 , 9 months 148 @entity1 ; 12 months, 144 @entity1 . Time to nadir was not a significant determinant of outcome. @entity1486 levels at 3 and 6 months and the nadir level were individually highly correlated with outcome. In multivariate analyses of posttreatment values, only the nadir value was independently significant, with increasing relapse rates as its value was higher. It retained significance when pretreatment PSA level was included in the model. Nadir values ranged from undetectable (52 @entity1 ) to 20.3 ng/ml with a median of 1.1 ng/ml. Nadir values down to 1 ng/ml were prognostic; below 1 ng/ml (182 @entity1 ) the nadir value no longer yielded prognostic information additional to that inherent in the pretreatment value. Only @entity1 with nadir levels < 1 ng/ml fared well (5-year incidence of relapse or rising PSA 17%); however, if the pretreatment level exceeded 30 ng/ml, then even a nadir level < 1 ng/ml was associated with a 40% failure rate at 5 years. CONCLUSION: The nadir PSA value after radiation is a significant posttreatment determinant of outcome and was second only to the pretreatment value. Surprisingly low nadir values were prognostically significant. Only @entity1 whose nadir falls below 1 ng/ml can be said to have achieved a biochemical complete remission. However, even such low nadir values do not portend durable disease control for @entity1 with high pretreatment PSA levels.

title: Serum @entity1486 after radiation therapy for clinically localized XXXX : prognostic implications.

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: UNASSIGNED: The prompt diagnosis and treatment of @entity30106 is critical, but culture is insensitive (1, 3).-beta-D-glucan (BDG) is FDA-approved for serologic diagnosis of invasive @entity364 . However, BDG is not approved for @entity2841 and the appropriate cutoff is unknown. We aim to validate the diagnostic accuracy of @entity2841 BDG for @entity30106 among @entity1 exposed to contaminated @entity8745 (MPA). A retrospective observational study was conducted at St. Joseph Mercy Hospital and Vanderbilt University from November, 2013 - February, 2014. @entity1 were included if they received a contaminated MPA injection. Cases were classified as probable or proven @entity693 according to Centers for Disease Control and Prevention guidelines. @entity2841 BDG testing was performed according to the package insert for serum and validated using Clinical Laboratory Standards Institute procedures (MiraVista Diagnostics). Of 233 @entity1 , 45 had @entity693 (28 proven), 53 had spinal/paraspinal infection (19 proven), and 135 did not develop disease. Using the manufacturer's cutoff (>=  80 pg/mL), the sensitivity and specificity were 96% and 95% for proven @entity693 ; and 84% and 95% for probable or proven @entity693 . The Receiver Operating Characteristic analysis identified the optimal cutoff for proven @entity693 to be 66 pg/mL (sensitivity 100%, specificity 94%); for probable or proven @entity693 to be 66 pg/mL (sensitivity 91%, specificity 92%). Our results suggest that @entity2841 BDG is highly sensitive and specific for diagnosis of @entity30106 associated with contaminated MPA injections. Further study is needed on the utility of @entity2841 BDG for other types of @entity30106 .

title: @entity2841 (1,3)-Beta-D-Glucan for the Diagnosis of F XXXX Associated with Contaminated Methylprednisolone Injections.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity30106 :: ('MESH:D016921', 'Disease') :: ['fungal meningitis']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['meningitis']

entities_list: @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal disease']

entities_list: @entity8745 :: ('MESH:C000873', 'Chemical') :: ['methylprednisolone acetate']

entities_list: @entity2841 :: ('1437', 'Gene') :: ['CSF', 'cerebrospinal fluid (CSF)']

answer: @entity30106 :: (MESH:D016921,Disease) :: ['Fungal Meningitis']


abstract: UNASSIGNED: The prompt diagnosis and treatment of @entity30106 is critical, but culture is insensitive (1, 3).-beta-D-glucan (BDG) is FDA-approved for serologic diagnosis of invasive @entity364 . However, BDG is not approved for @entity2841 and the appropriate cutoff is unknown. We aim to validate the diagnostic accuracy of @entity2841 BDG for @entity30106 among @entity1 exposed to contaminated @entity8745 (MPA). A retrospective observational study was conducted at St. Joseph Mercy Hospital and Vanderbilt University from November, 2013 - February, 2014. @entity1 were included if they received a contaminated MPA injection. Cases were classified as probable or proven @entity693 according to Centers for Disease Control and Prevention guidelines. @entity2841 BDG testing was performed according to the package insert for serum and validated using Clinical Laboratory Standards Institute procedures (MiraVista Diagnostics). Of 233 @entity1 , 45 had @entity693 (28 proven), 53 had spinal/paraspinal infection (19 proven), and 135 did not develop disease. Using the manufacturer's cutoff (>=  80 pg/mL), the sensitivity and specificity were 96% and 95% for proven @entity693 ; and 84% and 95% for probable or proven @entity693 . The Receiver Operating Characteristic analysis identified the optimal cutoff for proven @entity693 to be 66 pg/mL (sensitivity 100%, specificity 94%); for probable or proven @entity693 to be 66 pg/mL (sensitivity 91%, specificity 92%). Our results suggest that @entity2841 BDG is highly sensitive and specific for diagnosis of @entity30106 associated with contaminated MPA injections. Further study is needed on the utility of @entity2841 BDG for other types of @entity30106 .

title: XXXX (1,3)-Beta-D-Glucan for the Diagnosis of F @entity30106 Associated with Contaminated Methylprednisolone Injections.

answer: @entity2841 :: (1437,Gene) :: ['Cerebrospinal Fluid']


abstract: The vascular selectins P- and @entity4105 are inducible adhesion proteins expressed by endothelial cells that have been shown to support shear-dependent rolling of myeloid cells. This interaction is thought to be a prerequisite event for subsequent steps, such as tight adhesion/aggregation and transendothelial cell migration, involved in the accumulation of leukocytes into tissues. Certain lymphocyte subsets have also been shown to bind the vascular selectins, but the importance of this interaction in mediating shear-dependent rolling, as described for myeloid cells, has not been demonstrated. We expand on our earlier observation that @entity291 gamma/delta T cells bind @entity4105 by showing that this interaction leads to a reproducible rolling event in assays done under shear forces that approximate those that occur in vivo. @entity4105 , expressed by L cell transfectants or cytokine-stimulated @entity1 and @entity291 endothelial cells, equally supports the shear-dependent rolling interaction. The lymphocyte adhesion proteins L-selectin, @entity27217 , and @entity42087 do not contribute to this event. @entity53170 treatment of the gamma/delta T cells or addition of @entity1098 to the assay completely blocks the rolling interaction. We further show for the first time that @entity8729 expressed by @entity556 -activated platelets or a soluble @entity8729 / @entity1 Ig chimera specifically binds gamma/delta T cells. The @entity8729 interaction is similar to the rolling event mediated by @entity4105 --it requires divalent cations and @entity3167 on the lymphocyte, it lacks involvement of L-selectin and @entity27217 , and rolling occurs under physiologic shear conditions. These results provide the documentation that the vascular selectins can support shear-dependent rolling of a lymphocyte subset and that @entity8729 mediates the adhesion of gamma/delta T cells.

title: Cell surface P- and @entity4105 support shear-dependent rolling of XXXX gamma/delta T cells.

entities_list: @entity3167 :: ('MESH:D019158', 'Chemical') :: ['sialic acid']

answer: @entity291 :: (9913,Species) :: ['bovine']


abstract: The vascular selectins P- and @entity4105 are inducible adhesion proteins expressed by endothelial cells that have been shown to support shear-dependent rolling of myeloid cells. This interaction is thought to be a prerequisite event for subsequent steps, such as tight adhesion/aggregation and transendothelial cell migration, involved in the accumulation of leukocytes into tissues. Certain lymphocyte subsets have also been shown to bind the vascular selectins, but the importance of this interaction in mediating shear-dependent rolling, as described for myeloid cells, has not been demonstrated. We expand on our earlier observation that @entity291 gamma/delta T cells bind @entity4105 by showing that this interaction leads to a reproducible rolling event in assays done under shear forces that approximate those that occur in vivo. @entity4105 , expressed by L cell transfectants or cytokine-stimulated @entity1 and @entity291 endothelial cells, equally supports the shear-dependent rolling interaction. The lymphocyte adhesion proteins L-selectin, @entity27217 , and @entity42087 do not contribute to this event. @entity53170 treatment of the gamma/delta T cells or addition of @entity1098 to the assay completely blocks the rolling interaction. We further show for the first time that @entity8729 expressed by @entity556 -activated platelets or a soluble @entity8729 / @entity1 Ig chimera specifically binds gamma/delta T cells. The @entity8729 interaction is similar to the rolling event mediated by @entity4105 --it requires divalent cations and @entity3167 on the lymphocyte, it lacks involvement of L-selectin and @entity27217 , and rolling occurs under physiologic shear conditions. These results provide the documentation that the vascular selectins can support shear-dependent rolling of a lymphocyte subset and that @entity8729 mediates the adhesion of gamma/delta T cells.

title: Cell surface P- and XXXX support shear-dependent rolling of @entity291 gamma/delta T cells.

answer: @entity4105 :: (6401,Gene) :: ['E-selectin']


abstract: There are few reliable prognostic markers of biological @entity146 for @entity135 in general. For @entity189 , anatomic location, @entity5 size, histological grade, and extent of disease involvement are considered to be clinically important risk factors for recurrent disease. Molecular genetic alterations in @entity189 have not been characterized, and @entity5 cell proteins have not been shown to be prognostically significant. Here a cohort of @entity3975 of the major (parotid and submandibular) salivary glands are analyzed for a molecular @entity74 , @entity1722 gene amplification, and gene amplification and expression results are compared with long-term clinical follow-up information. Archival tissues resected from 58 @entity1 with @entity3975 of salivary glands were evaluated for @entity1722 gene amplification by fluorescence in situ hybridization and for gene expression by immunohistochemistry in a blinded fashion. Clinical follow-up information was compared with the results of these analyses to determine whether there were significant associations. Overexpression, identified as membrane immunostaining by immunohistochemistry, was observed in 22 of 58 (38%) @entity3975 . Gene amplification, characterized by fluorescence in situ hybridization, was observed in 12 (21%) cases. Eleven of the 12 cases with gene amplification were also immunostained for @entity1722 . Both gene amplification (P = 0.0001, P < 0.0001) and immunostaining (P < 0.0001, P < 0.0001) were correlated with @entity66 and poorer overall @entity1 survival, respectively. Multivariate analysis showed that @entity1722 immunostaining and amplification were markers of poor prognosis independent of histopathological grade, @entity5 size, and involvement of regional lymph nodes. @entity1722 is amplified and/or overexpressed in approximately one-third of @entity3975 of salivary glands. Amplification and/or overexpression appears to be an independent marker of poor prognosis in @entity3975 of the salivary glands as it is in @entity189 of the breast, ovary, and endometrium.

title: Amplification and overexpression of XXXX in @entity189 of the salivary gland: correlation with poor prognosis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity135 :: ('MESH:D006258', 'Disease') :: ['head and neck carcinomas']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['shorter disease-free interval']

entities_list: @entity3975 :: ('MESH:D018277', 'Disease') :: ['mucoepidermoid carcinoma', 'mucoepidermoid carcinomas']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressiveness']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas', 'salivary gland carcinomas']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic alteration']

answer: @entity1722 :: (2064,Gene) :: ['HER-2/neu']